CANbridge Pharmaceuticals Inc.

HK$1.65As of Sun 8 Nov 2026, 12:00 UTC
HKEX:1228Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 5Y CAGR (29.34%)
Div yield —
ROE —
Biotechnology
Beta (5Y) (0.13)
PE TTM —
TSR TTM (16.50%)
Mkt cap HK$982.8M
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.74
5.61%
(20.05%)
Hold 8|10|8|7|6
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.05
0.05
0.05
0.05
30.66%
33.76%
23.85%
11.98%
Revenue¥M
100.2
102.9
107.2
107.9
16.41%
14.64%
17.73%
12.07%
Peers (US$125.4M)
Cap (US$)
PE
124.7M
—
Capital
TTM
5Y
10Y
Leveragex
0.614
(1.118)
(0.981)
EBIT/Intx
3.642
0.072
0.074
Own earn%
10.32
(56.97)
(60.79)
Sh yield%
14.84
18.14
20.53
Owners
Insiders/Inst%
9.11
83.51
Short interest%
5.74
SBC / revenue%
1.88
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
11–16
$1 testx
−0.2
Incr. ROIC%
11